Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis

Background: Lacking head-to-head trial, the optimal treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure is unclear. This study is to compare the efficacy and safety of systemic treatments in patients who progressed after docetaxel to aid clinic...

Full description

Bibliographic Details
Main Authors: Junru Chen, Yaowen Zhang, Xingming Zhang, Jinge Zhao, Yuchao Ni, Sha Zhu, Ben He, Jindong Dai, Zhipeng Wang, Zilin Wang, Jiayu Liang, Xudong Zhu, Pengfei Shen, Hao Zeng, Guangxi Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
metastatic castration-resistant prostate cancer
network meta-analysis
docetaxel (DOC)
enzalutamide (ENZ)
abirateron
radium-223 (Ra) 223
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.789319/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.789319/full

Similar Items